Antenatal corticosteroid therapy administered to pregnant individuals at risk of preterm birth significantly accelerates fetal lung maturation, reducing the incidence of neonatal respiratory distress syndrome, according to clinical guidelines from the American College of Obstetricians and Gynecologists (ACOG). When maternal-fetal medicine (MFM) specialists identify complications such as abnormal umbilical cord blood flow or other indicators of uteroplacental insufficiency during the third trimester, hospital admission for targeted interventions is often required to optimize neonatal outcomes.
Indications for Antenatal Corticosteroids in Preterm Risk
Obstetric care providers evaluate fetal well-being using biophysical profiles, non-stress tests, and Doppler ultrasound of the umbilical artery to assess placental function. According to ACOG and the Society for Maternal-Fetal Medicine (SMFM), a course of corticosteroids—typically betamethasone—is recommended for pregnant individuals between 24 weeks and 34 weeks of gestation who are at imminent risk of preterm delivery within seven days. Administration is also considered for select patients between 34 and 36 weeks of gestation who have not received a previous course and remain at risk for late preterm birth.
When MFM specialists detect compromised cord blood parameters, it signals potential fetal distress or growth restriction. Hospital admission allows clinical teams to monitor fetal heart rates continuously, administer the two-dose intramuscular steroid regimen 24 hours apart, and prepare neonatal intensive care unit (NICU) resources if delivery becomes necessary.
Clinical Benefits and Mechanism of Action
Corticosteroids cross the placenta to stimulate structural and biochemical changes in the fetal lung tissue, primarily by enhancing the production and release of surfactant. Surfactant is a complex lipoprotein mixture that lowers surface tension in the alveoli, preventing alveolar collapse at the end of expiration.
Clinical trials synthesized in Cochrane Systematic Reviews demonstrate that antenatal corticosteroid therapy decreases neonatal mortality, respiratory distress syndrome, and intraventricular hemorrhage in preterm infants. The maximum benefit occurs when delivery happens at least 24 hours after the initiation of the first dose and within seven days of treatment completion.
Monitoring and Hospital Management
Hospitalization during suspected placental or umbilical cord compromise ensures timely maternal and fetal surveillance. Medical teams track uterine activity, maternal blood pressure, and fetal oxygenation to determine the optimal timing for delivery. If cord blood flow deteriorates further, indicating severe uteroplacental compromise, clinicians may expedite delivery via cesarean section, relying on the administered corticosteroids to mitigate neonatal respiratory complications.
Patients receive comprehensive counseling from multidisciplinary teams, including neonatologists, who discuss expected postnatal care and NICU readiness based on gestational age and administered therapies.